プロの翻訳者、企業、ウェブページから自由に利用できる翻訳レポジトリまで。
7
7
最終更新: 2014-08-15
使用頻度: 32
品質:
7.
7th
最終更新: 2011-10-23
使用頻度: 1
品質:
7 ára
7 yrs
最終更新: 2017-04-26
使用頻度: 1
品質:
7 daga.
7 days.
最終更新: 2017-04-26
使用頻度: 1
品質:
fall 7:
function & 7:
最終更新: 2011-10-23
使用頻度: 1
品質:
警告:見えない HTML フォーマットが含まれています
skref 7
step 7
最終更新: 2017-04-26
使用頻度: 4
品質:
7 dælur.
7 syringes.
最終更新: 2017-04-26
使用頻度: 1
品質:
7 aðildarríki:
7 member states:
最終更新: 2014-02-06
使用頻度: 1
品質:
p.f396fs*7
p.f396fs 7
最終更新: 2017-04-26
使用頻度: 1
品質:
algengar: 7 (7)
common: 7 (7)
最終更新: 2017-04-26
使用頻度: 1
品質:
60-64 ára n=359-404
60-64 years n=359-404
最終更新: 2017-04-26
使用頻度: 1
品質:
af sarkmeinssjúklingunum 404 hættu 2 sjúklingar á meðferð með eribúlíni vegna úttaugakvilla.
out of the 404 sarcoma patients, 2 patients discontinued treatment with eribulin due to peripheral neuropathy.
最終更新: 2017-04-26
使用頻度: 1
品質:
b 388 sjúklingar metnir í hópnum sem fékk meðferð með gemcítabíni c 404 sjúklingar metnir í hópnum sem fékk meðferð með abraxane/gemcítabíni
b 388 patients assessed in gemcitabine-treated group c 404 patients assessed in abraxane/gemcitabine-treated group
最終更新: 2017-04-26
使用頻度: 1
品質:
brjóstakrabbamein n=404 (1-5%) ekki áður tilkynnt um í klínískum rannsóknum
breast cancer n=404 (1-5%) not previously reported in clinical trials
最終更新: 2017-04-26
使用頻度: 1
品質:
aukaverkanir roflumilasts í rannsókn ro-2455-404-rd voru í samræmi við það sem þegar liggur fyrir í kafla 4.8.
the observed adverse reactions for roflumilast in study ro-2455- 404-rd were in line with those already included in section 4.8.
最終更新: 2017-04-26
使用頻度: 1
品質: